--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial ...

Combining semaglutide with muscle-preserving antibodies protected lean mass – sparing approximately 50%-80% of the lean mass lost with semaglutide alone – while also increasing loss of fat mass ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4 trial, retatrutide, a first-in-class glucose-dependent insulinotropic polypeptide (GIP), ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 Advancing NA-931, the first oral quadruple receptor ...

After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and ...